MDA Venture Philanthropy Funds Preclinical Development of Catabasis Pharma‘s Anti-Inflammatory Drugs

Massachusetts-based Catabasis Pharmaceuticals’ has been awarded MVP funding to test two of its orally available small molecule drugs in mouse models of Duchenne muscular dystrophy. The anti-inflammatory properties of CAT-1004 and CAT-1040 are believed to hold potential for the treatment of DMD and other neuromuscular diseases, including ALS, given their ability to reduce macrophage-induced inflammation and improve neuromuscular function.

Massachusetts-based Catabasis Pharmaceuticals’ has been awarded MVP funding to test two of its orally available small molecule drugs in mouse models of Duchenne muscular dystrophy. The anti-inflammatory properties of CAT-1004 and CAT-1040 are believed to hold potential for the treatment of DMD and other neuromuscular diseases, including ALS, given their ability to reduce macrophage-induced inflammation and improve neuromuscular function.

Click here to read more.

Share this:
Facebooktwittergoogle_plusmailFacebooktwittergoogle_plusmail